China Approves Sanofi’s Myqorzo and Redemplo for Cardiovascular and Rare Metabolic Diseases

Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome Underscores Sanofi’s long-ter...

January 16, 2026 | Friday | News
Swissmedic Approves Santhera’s AGAMREE® for Duchenne Muscular Dystrophy

Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products (Swissmedic), has approved AGAMREE® (vamorolone) for th...

January 16, 2026 | Friday | News
Stablepharma and AFT Pharmaceuticals Partner to Develop Fridge-Free Sterile Injectables for Global Markets

  Stablepharma Limited, specialists in thermostable formulations,announced a development and option-to-license agreement with AFT Pharmaceuticals to ...

January 16, 2026 | Friday | News
Hongene Biotech Secures Gates Foundation Grant to Advance Equitable mRNA Vaccine Manufacturing

Hongene Biotech announced the receipt of a grant from the Gates Foundation to develop high-quality, affordable, and patent-free cap analogs for use ...

January 14, 2026 | Wednesday | News
Charles River to Acquire K.F. Cambodia and PathoQuest, Strengthening DSA Supply Chain and Expanding NAMs Capabilities

Signs Agreement to Acquire K.F. (Cambodia) Ltd. to Further Strengthen DSA Supply Chain; Transaction Expected to be Accretive to Non-GAAP Earnin...

January 13, 2026 | Tuesday | News
Alnylam CEO Yvonne Greenstreet Outlines Five-Year Strategy as Company Reports Strong 2025 Growth and 2026 Outlook

− Full Year 2025 Preliminary* Net Product Revenues of $2,987 Million (81% Growth vs. 2024), Driven Primarily by Preliminary* Total TTR Revenues o...

January 13, 2026 | Tuesday | Company results
Enginzyme and AGC Present Scalable Manufacturing Process for Key mRNA Ingredient m¹ΨTP

At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-met...

January 13, 2026 | Tuesday | News
QIAGEN CEO Thierry Bernard Outlines 2026 Growth Priorities to Accelerate Path to $2 Billion in Pillar Sales by 2028

Building on strong momentum in 2025, new product launches and regulatory milestones planned for 2026 to support goal of at least $2 billion in combined...

January 13, 2026 | Tuesday | Company results
Etienna Bio Secures Exclusive Global License From UMass Chan for Adipose-Derived Cell and Matrix Platform

Etienna Bio, Inc., a biotechnology company focused on next-generation autologous and cell-enabled biomaterials for regenerative and aesthetic application...

January 12, 2026 | Monday | News
Shilpa Medicare’s OERIS™ Clears Phase 3, Showing Superior Convenience, Efficacy and Safety in CINV

Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondans...

January 12, 2026 | Monday | News
Tensive Reports Positive Pivotal Trial Results for REGENERA™ in Lumpectomy Patients

Clinical data from pivotal trial in patients undergoing lumpectomy confirm strong safety profile and growing performance benefits Primary safety endp...

January 09, 2026 | Friday | News
Early Prescriber Confidence Is Clear,” Says LENZ Therapeutics CEO Eef Schimmelpennink as VIZZ Launch Exceeds Expectations

Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-...

January 09, 2026 | Friday | Company results
HUTCHMED’s Sovleplenib Meets Primary Endpoint in Phase III ESLIM-02 Trial in wAIHA

— Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease —  HUTCHMED (China) Lim...

January 08, 2026 | Thursday | News
HealthBiome Secures Dual U.S. FDA and Korean MFDS Approvals for Akkermansia Postbiotic with Muscle Health Claim

Akkermansia muciniphila postbiotic receives both U.S. FDA dietary supplement clearance and Korean functional ingredient approval with muscle health ...

January 08, 2026 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close